Image de couverture de livre

Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma

Abstract The prognosis of adult T-cell leukemia-lymphoma (ATL) remains very poor, and there is an urgent clinical need to investigate novel therapies for ATL. The expression of phosphatidylinositol 3-kinase-δ (PI3k-δ) is normally restricted to hematopoietic cells and is known as a key determinant of...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Hiroo Katsuya (Auteur), Lucy B. M. Cook (Auteur), Aileen G. Rowan (Auteur), Yorifumi Satou (Auteur), Graham P. Taylor (Auteur), Charles R. M. Bangham (Auteur)
Format:	Livre
Publié:	BMC, 2018-07-01T00:00:00Z.
Sujets:	article
Accès en ligne:	Connect to this object online.
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase δ syndrome
par: Amika K. Sood, et autres
Publié: (2023)

Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes
par: Vyanka Redenbaugh, et autres
Publié: (2021)

Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment
par: Vassilios Lougaris, et autres
Publié: (2024)

Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype
par: Peiwei Zhao, et autres
Publié: (2024)

Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor
par: Yu Cai, et autres
Publié: (2020)

Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors
par: Minhang Xin, et autres
Publié: (2018)

Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient
par: Francesca Conti, et autres
Publié: (2021)

Deficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani.
par: Forough Khadem, et autres
Publié: (2014)

Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies
par: Shuwen Jiang, et autres
Publié: (2024)

Case Report: Early-onset or recalcitrant cytopenias as presenting manifestations of activated PI3Kδ syndrome
par: Allison S. Remiker, et autres
Publié: (2024)

Effect of Azelaic Acid on Psoriasis Progression Investigated Based on Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (AKT) Signaling Pathway
par: Li L, et autres
Publié: (2022)

Corrigendum: Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient
par: Francesca Conti, et autres
Publié: (2021)

Analysis of some flavonoids for inhibitory mechanism against cancer target phosphatidylinositol 3-kinase (PI3K) using computational tool
par: Mohd Suhail, et autres
Publié: (2023)

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
par: Wennan Zhao, et autres
Publié: (2017)

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor
par: Tory Starzyk, MA, et autres
Publié: (2022)

Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling
par: Nidia Moreno-Corona, et autres
Publié: (2021)

Quatramer™ encapsulation of dual‐targeted PI3‐Kδ/HDAC6 inhibitor, HSB‐510, suppresses growth of breast cancer
par: Sachchidanand Tiwari, et autres
Publié: (2023)

Changing nitrogen deposition with low δ15N−NH4+ and δ15N−NO3− values at the Experimental Lakes Area, northwestern Ontario, Canada
par: J.J. Venkiteswaran, et autres
Publié: (2017)

Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity
par: Jungeun Lee, et autres
Publié: (2022)

Case Report: Intestinal Nodular Lymphoid Hyperplasia as First Manifestation of Activated PI3Kδ Syndrome Due to a Novel PIK3CD Variant
par: Antonio Marzollo, et autres
Publié: (2021)

Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin's lymphoma, in healthy Chinese volunteers
par: Chun-Yang Zhao, et autres
Publié: (2024)

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.
par: Elizabeth A Nelson, et autres
Publié: (2017)

Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
par: Mohamed E. Shaker, et autres
Publié: (2023)

Mono- and di-thiocarbamate inhibition studies of the δ-carbonic anhydrase TweCAδ from the marine diatom Thalassiosira weissflogii
par: Silvia Bua, et autres
Publié: (2018)

Effects of chronic Δ9-tetrahydrocannabinol treatment on Rho/Rho-kinase signalization pathway in mouse brain
par: Halil Mahir Kaplan, et autres
Publié: (2017)

Reduction of Neuroinflammation by δ-Opioids Via STAT3-Dependent Pathway in Chronic Glaucoma Model
par: Shahid Husain, et autres
Publié: (2021)

Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer
par: Vicenç Ruiz de Porras, et autres
Publié: (2024)

ΔMST and the Regulation of Cardiac CSE and OTR Expression in Trauma and Hemorrhage
par: Britta Trautwein, et autres
Publié: (2021)

Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
par: Mohamed E. Shaker, et autres
Publié: (2023)

The Phosphatidylinositol 3-Kinase/mTor Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration
par: David Heras-Sandoval, et autres
Publié: (2011)

The Role of Phosphatidylinositol-3-Kinase and AMP-Activated Kinase in the Rapid Estrogenic Attenuation of Cannabinoid-Induced Changes in Energy Homeostasis
par: Edward J. Wagner, et autres
Publié: (2011)

The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma
par: Min Hye Jang, et autres
Publié: (2015)

Glucose Uptake in Rat Skeletal Muscle L6 Cells Is Increased by Low-Intensity Electrical Current Through the Activation of the Phosphatidylinositol-3-OH Kinase (PI-3K) / Akt Pathway
par: Shuichiro Yano, et autres
Publié: (2011)

Protein Kinase C-δ Mediates Shedding of Angiotensin-Converting Enzyme 2 from Proximal Tubular Cells
par: Fengxia eXiao, et autres
Publié: (2016)

Increased Sensitivity of Mice Lacking Extrasynaptic δ-Containing GABAA Receptors to Histamine Receptor 3 Antagonists
par: Shamsiiat Abdurakhmanova, et autres
Publié: (2020)

Pharmacokinetics, bioavailability, metabolism and excretion of δ-viniferin in rats
par: Ping Mao, et autres
Publié: (2016)

Notoginsenoside R1, a metabolite from Panax notoginseng (Burkill) F.H.Chen, stimulates insulin secretion through activation of phosphatidylinositol 3-kinase (PI3K)/Akt pathway
par: Altaf Al-Romaiyan, et autres
Publié: (2024)

Activated PI3Kδ syndrome 1 mimicking systemic lupus erythematosus and secondary Sjögren's syndrome-like phenotype without recurrent infections: A case report
par: Jing Yin, et autres
Publié: (2022)

Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B‐cell malignancies: Results from the CITADEL‐101 study
par: Jia Li, et autres
Publié: (2024)

Thrombin Promotes Matrix Metalloproteinase-13 Expression through the PKCδ/c-Src/EGFR/PI3K/Akt/AP-1 Signaling Pathway in Human Chondrocytes
par: Chun-Yin Huang, et autres
Publié: (2013)